Albemarle Announces Idling of Operations at Kemerton Processing Plant
Albemarle Corporation ALB recently announced that it will idle Train 1, the remaining operating train at its Kemerton lithium hydroxide processing plant in Western Australia, and place it into care and maintenance effective immediately. This move follows earlier actions in 2024 to idle Train 2 for care and maintenance and stop expansion plans for Trains 3 and 4.
The Kemerton facility processes spodumene from the Greenbushes mine, one of the world’s best deposits. Albemarle holds an ownership stake and half of the offtake rights from Greenbushes through a joint venture. The Kemerton plant was set up to support the development of a lithium supply chain in Western Australia, leveraging its advanced technology at a commercial scale.
The company’s decision is a result of ongoing efforts over the past two and a half years to reduce operating costs amid periods of price volatility. The improvement in lithium prices has also remained insufficient to offset the challenges facing Western hard-rock lithium conversion operations.
The company expects higher flexibility and optionality to benefit adjusted EBITDA starting in the second quarter of 2026. No impact is expected on projected 2026 sales volumes. Albemarle’s Australian mining interests, including its stakes in Greenbushes and Wodgina, as well as regional exploration assets, will also remain unaffected as they are central to the company’s strategy.
ALB stock has gained 104.8% over the past year compared with the industry’s 13.3% decline.
Image Source: Zacks Investment Research
ALB’s Zacks Rank & Other Key Picks
ALB currently sports a Zacks Rank #1 (Strong Buy).
Some other top-ranked stocks in the Basic Materials space are Coeur Mining, Inc. CDE, Fortuna Mining Corp. FSM and Avino Silver & Gold Mines Ltd. ASM.
While CDE and FSM sport a Zacks Rank #1 each at present, ASM carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
The Zacks Consensus Estimate for CDE’s 2025 earnings is pegged at 91 cents per share, indicating a rise of 405.56% year over year. Its earnings beat the Zacks Consensus Estimate in two of the trailing four quarters while missing it in the remaining two, with an average surprise of 106.61%. CDE’s shares have soared 239.2% over the past year.
The Zacks Consensus Estimate for FSM’s 2025 earnings is pinned at 73 cents per share, indicating a 58.7% year-over-year increase. Its shares have surged 114.6% over the past year.
The Zacks Consensus Estimate for ASM’s 2025 earnings is pinned at 17 cents per share, indicating a 13.33% year-over-year increase. ASM’s shares have skyrocketed 614.6% over the past year.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Will the traditional Christmas rally still happen in the US stock market this year?
After a simultaneous technical and position-based recovery in the US stock market, Goldman Sachs, Morgan Stanley, and JPMorgan have successively signaled a year-end rebound. Extremely light positions, mean reversion of valuations, and seasonal support together create conditions for a short squeeze. However, global manufacturing import price inflation has annualized at around 24%, surpassing the pandemic peak, and the inflation bill will come due intensively in the first quarter of next year. Goldman Sachs warns that once the year-end rally materializes, it may exhaust future upside potential.

Anthropic IPO Roadshow: CEO Says "Doesn't Care About Market Conditions", Hopes to "Underpromise and Overdeliver"
As Anthropic gears up for its IPO, CEO Amodei remains deliberately low-key during the roadshow, emphasizing "under-promise and over-deliver," and appears calm regarding market volatility at the time of listing. In response to fluctuations in the AI sector and the Nvidia situation, Amodei stated he is not particularly concerned about the specific month of listing or market conditions, and frankly admits that allocation of computing power is "the most fundamental business challenge."
SpaceX (SPCX.US) Starship's 15th Test Flight: Booster recovery failed for unknown reasons; first orbital round-trip mission still awaits upper stage "tower catch" landing
On Friday local time, SpaceX conducted its 15th Starship flight mission in Texas.

Unlike Elon Musk’s “One Price” Approach: Anthropic (ANT.US) Roadshow Pricing Inquiry at $70-78, Institutional Investors Become the True Decision Makers in IPO Pricing
Anthropic will launch what is set to be the largest IPO in history next week, aiming to take this title from SpaceX. However, unlike Elon Musk’s conglomerate, large investors will have greater influence over its IPO pricing amid the ongoing turbulence in the artificial intelligence (AI) market.
